Get started
Author

Alexandros Georgiou

Circulating tumour DNA, a promising biomarker for the management of colorectal cancer
2017 · Shelize Khakoo, Alexandros Georgiou, et al. · Critical Reviews in Oncology/Hematology · 45
Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer Center
2019 · Alexandros Georgiou, Shelize Khakoo, et al. · Cancers · 38
PDF
Inactivation of NF1 Promotes Resistance to EGFR Inhibition in KRAS/NRAS/BRAFV600 -Wild-Type Colorectal Cancer
2020 · Alexandros Georgiou, Adam Stewart, et al. · Molecular Cancer Research · 29
Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World Study
2022 · Daniel Johnathan Hughes, Matthaios Kapiris, et al. · Cancers · 24
PDF
Mental Health and Adherence to COVID-19 Protective Behaviors among Cancer Patients during the COVID-19 Pandemic: An International, Multinational Cross-Sectional Study
2021 · Angelos P. Kassianos, Alexandros Georgiou, et al. · Cancers · 22
PDF
Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS -Mutant Cancers
2019 · Adam Stewart, Elizabeth A. Coker, et al. · Molecular Cancer Therapeutics · 19
A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments
2017 · Anna Minchom, Parames Thavasu, et al. · PLoS ONE · 18
PDF
Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma
2018 · KokHaw Jonathan Lim, Lavinia Spain, et al. · ESMO Open · 15
PDF
[99mTc]-labelled anti-Programmed Death-Ligand 1 single-domain antibody SPECT/CT: a novel imaging biomarker for myocardial PD-L1 expression
2023 · Muhummad Sohaib Nazir, Daniel Johnathan Hughes, et al. · EJNMMI Research · 11
PDF
Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC)
2015 · Heike Seifert, Alexandros Georgiou, et al. · Gynecologic Oncology · 11
LysNDeNovo: An algorithm enabling de novo sequencing of Lys‐N generated peptides fragmented by electron transfer dissociation
2010 · Bas van Breukelen, Alexandros Georgiou, et al. · PROTEOMICS · 9
A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAFV600 wild-type colorectal cancer
2021 · Alexandros Georgiou, Adam Stewart, et al. · Cellular Oncology · 8
PDF
Predictors and Outcomes of Non-Small Cell Lung Carcinoma Patients Following Severe Immune Checkpoint Inhibitor Toxicity: A Real-World UK Multi-Centre Study
2025 · Umair Mahmood, Eleni Josephides, et al. · Cancers · 4
PDF
PD-L1 imaging with [99mTc]NM-01 SPECT/CT is associated with metabolic response to pembrolizumab with/without chemotherapy in advanced lung cancer
2025 · Daniel Johnathan Hughes, Gitasha Chand, et al. · British Journal of Cancer · 4
PDF
Real-World Analysis of Survival and Treatment Efficacy in Stage IIIA-N2 Non-Small Cell Lung Cancer
2024 · Eleni Josephides, Roberta Dunn, et al. · Cancers · 2
Temporospatial heterogeneity of acquired resistance mechanisms in EGFR-mutant lung adenocarcinoma: A case of concurrent EGFR mutation and small cell transformation
2021 · Daniel Johnathan Hughes, Gary JR Cook, et al. · Current Problems in Cancer Case Reports · 2
PDF
Comment on ‘Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer’—No support for de-escalation of immunotherapy
2019 · Alexandros Georgiou, Anna Minchom, et al. · European Journal of Cancer · 2
PP01.59: ABBIL1TY NSCLC-06: A Global, Randomized, Open-Label, Phase 3 Trial of Acasunlimab in Combination with Pembrolizumab vs Docetaxel in Checkpoint Inhibitor–Experienced Patients with PD-L1+ Metastatic Non-Small Cell Lung Cancer
2026 · Luis Paz-Ares, Benjamin Besse, et al. · Journal of Thoracic Oncology · 1
Outcomes Following Radiotherapy for Oligoprogressive NSCLC on Immune Checkpoint Inhibitors: A Real-World, Multinational Experience
2025 · Umair Mahmood, Eleni Josephides, et al. · Cancers · 1
PDF
93 Evaluating real-world tepotinib-related toxicity data across five UK cancer units- A case-series
2024 · Afxentiou Thalia, Spyros Gennatas, et al. · Lung Cancer · 1
Real-world outcomes with nivolumab for pre-treated malignant mesothelioma in the UK
2022 · Cienne Morton, Spyridon Gennatas, et al. · Lung Cancer · 1
KRAS mutant and RAS/BRAF wild type colorectal cancer cells exhibit differences in the rewiring of signal transduction that can impact on future therapeutic strategies
2018 · A. Georgiou, A. Stewart, et al. · Annals of Oncology · 1
Unravelling the context specificity of signalling in KRAS mutant cancers: Implications for design of clinical trials
2018 · U. Banerji, A. Stewart, et al. · Annals of Oncology · 1
Clinical trial end points relevant to patients and society for rare cancers
2015 · Shelize Khakoo, Alexandros Georgiou, et al. · Clinical Investigation · 1
A restrospective analysis of toxicities encountered with palliative epirubicin, oxaliplatin, and capecitabine (EOX) chemotherapy for advanced esophagogastric cancer.
2014 · Shelize Sadrudin Khakoo, Alexandros Georgiou, et al. · Journal of Clinical Oncology · 1
Works count: 84
Citation count: 271
H-index: 10
I10-index: 10
Year
Topic
Type